Oppenheimer analyst Suraj Kalia lowered the firm’s price target on Varex Imaging (VREX) to $23 from $30 and keeps an Outperform rating on the shares following Q1 results and Q2 guidance. The firm believes that Varex remains a deep-value name, with best in-class X-ray core competency, a “sticky” end-user base, and call options on cold cathode technology and photon counting detectors, despite the near-term pressures.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VREX: